Fortrea Holdings Inc.

Equities

FTRE

US34965K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
36.35 USD 0.00% Intraday chart for Fortrea Holdings Inc. +2.39% +4.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Fortrea Holdings Inc. Announces the Resignation of Betty Larson as from the Board, and All Board Committees CI
Baird Starts Fortrea Holdings With Neutral Rating, $43 Price Target MT
Transcript : Fortrea Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM
BofA Securities Adjusts Price Target on Fortrea to $33 From $29, Maintains Underperform Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday MT
Sector Update: Health Care MT
Transcript : Fortrea Holdings Inc., Q4 2023 Earnings Call, Mar 11, 2024
Powell's Remarks Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of CPI Data MT
Earnings Flash (FTRE) FORTREA HOLDINGS Reports Q4 Revenue $775.4M, vs. Street Est of $773.8M MT
Earnings Flash (FTRE) FORTREA HOLDINGS Reports Q4 EPS $0.19, vs. Street Est of $0.16 MT
CPI, Tech Outlooks Cap Wall Street Pre-Bell; Asia, Europe Off MT
Futures Down Pre-Bell Ahead of Key Inflation Data; Asia Churns, Europe Falls MT
Fortrea's Q4 Adjusted Earnings Fall, Revenue Rises; 2024 Revenue Guidance Issued; Agrees to Sell Enabling Services Segment MT
Fortrea sells enabling services and patient access businesses for up to $345 mln RE
Fortrea signs agreement to divest certain assets to Arsenal Capital Partners RE
Fortrea Holdings Inc. Provides Earnings Guidance for 2024 CI
Fortrea Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Fortrea Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Arsenal Capital Partners entered into a definitive agreement to acquire Endpoint Clinical and Patient Access Businesses of Fortrea Holdings Inc. for approximately $350 million. CI
Deutsche Bank Initiates Coverage on Fortrea With Hold Rating, $36 Price Target MT
Fortrea Announces Opening of Its Expanded Non-Commercial Specialty Pharmacy, Fortrearx, Located in Lake Mary, Florid CI
Barclays Cuts Price Target on Fortrea Holdings to $35 From $38, Maintains Overweight Rating MT
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results DJ
North American Morning Briefing : Central Bankers -2- DJ
Chart Fortrea Holdings Inc.
More charts
Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customers’ needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
36.35 USD
Average target price
40.06 USD
Spread / Average Target
+10.21%
Consensus
  1. Stock Market
  2. Equities
  3. FTRE Stock
  4. News Fortrea Holdings Inc.
  5. Sector Update: Health Care Stocks Lean Lower Premarket Monday